Clinical and Radiographic Evaluation of Using the Entire Papilla Preservation Technique With and Without Autogenous Bone Graft and Injectable Platelet Rich Fibrin in Treatment of Periodontal Intraosseous Defects

Launched by CAIRO UNIVERSITY · Mar 29, 2024

Keywords

ClinConnect Summary

This clinical trial is looking at new ways to treat specific types of gum disease known as isolated intrabony periodontal defects. These are pockets of infection that can occur in the bone around teeth, particularly in patients with a more advanced stage of gum disease called stage III periodontitis. The study will compare two methods: one that uses a technique called the entire papilla preservation technique with and without adding a bone graft (using a piece of the patient's own bone) and an injectable treatment called platelet-rich fibrin, which may help the healing process.

To participate in this trial, you need to be an adult aged 18 or older with a healthy overall health condition and a specific type of gum problem that meets certain criteria, including having a deep pocket around one tooth. Participants must also maintain good oral hygiene and be willing to follow up for six months. If you are taking medications that could affect your gum disease, are a heavy smoker, or are pregnant, you may not be eligible. If you qualify and choose to participate, you can expect to receive treatment and regular check-ups to monitor your progress and the health of your gums.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Patients with healthy systemic condition.
• • 2. Adult patients (18 years old and older).
• • 3. Patients with stage lll periodontitis, having one isolated intrabony defect with probing depth \>6mm, clinical attachment level\> 6mm and at least 4 mm intrabony component involving predominantly the interproximal area of the affected tooth.
• • 4. Patients with full mouth plaque score\<20%.
• • 5. Patients with full mouth bleeding score\<20%.
• • 6. Compliance with good oral hygiene.
• • 7. Patients accept 6-months follow-up period (cooperative patients).
• • 8. Patients provide an informed consent.
• Exclusion Criteria:
• • 1. Ongoing drug therapy that might have an impact on the clinical signs and symptoms of periodontitis.
• • 2. One wall intrabony defect.
• • 3. Defects that involve the buccal and lingual sites.
• • 4. Smokers ˃ 10 cigarettes / day.
• • 5. Pregnant and lactating females.